Communiqués CYCN THERNPV

Actions

CYCN

US23255M2044

Marché Fermé - Nasdaq 22:00:00 24/09/2026			Varia. 5j.	Varia. 1 janv.
37,19 ^USD	+15,14%		+10,29%	+318,34%

08/09	Korsana Biosciences, Inc. a finalisé l'acquisition de Cyclerion Therapeutics, Inc. (NasdaqCM:CYCN) auprès d'un groupe d'actionnaires dans le cadre d'une fusion inversée.	CI
04/08	Cyclerion Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

05/08	Cyclerion Therapeutics : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)	PU
01/04	Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement	BU
17/02	Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board	AQ
05/01	Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression	AQ
12/11	Cyclerion Therapeutics : Amendment to Annual Report (Form 10-K/A)	PU
23/09/25	Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company	AQ
18/12/24	Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth	AQ
17/12/24	Cyclerion Therapeutics : sGC Stimulator Portfolio Generates Revenues to Enable Company Growth Form 8 K	PU
17/12/24	Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth	AQ
07/08/24	Regina Graul, Ph.D., Promoted to Chief Executive Officer	AQ
04/12/23	Cyclerion Appoints Regina Graul, Ph.D., as President	AQ
01/12/23	Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator	AQ
01/08/23	Cyclerion Therapeutics, Inc. - Tisento Launches with $81 Million from Top-Tier Investor Syndicate and Promising Cyclerion Assets	AQ
31/07/23	Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets	AQ
01/06/23	CYCLERION THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
01/06/23	Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement	AQ
25/05/23	Cyclerion Therapeutics : Private Placement - Form 8-K	PU
25/05/23	CYCLERION THERAPEUTICS, INC. : Unregistered Sale of Equity Securities, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
15/05/23	Cyclerion Announces Reverse Stock Split	GL
12/05/23	CYCLERION THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Unregistered Sale of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
12/05/23	Cyclerion Announces Corporate Updates and Q1 2023 Financial Results	GL
12/05/23	Cyclerion Announces Definitive Agreement for Zagociguat and CY3018	GL
12/05/23	Cyclerion Announces Definitive Agreement for Zagociguat and CY3018	AQ
12/05/23	Cyclerion Announces Corporate Updates and Q1 2023 Financial Results	AQ
03/04/23	CYCLERION THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ